HexemBio, a biotech company developing regenerative therapies for aging blood stem cells, has raised $10.4M in seed funding led by Draper Associates. The company uses Synthetic Human Yolk Sac technology to rejuvenate hematopoietic stem cells (HSCs) ex vivo, restoring their youthful function for reinfusion. The capital will support IND submission in 2026 and first patient dosing in Q1 2027.
Longevity Funding Hits Record Highs
HexemBio's raise aligns with a surge in longevity biotech investments, where the sector attracted $3.74B across 41 deals in Q1 2026 alone. Competitors like Ensoma have raised $205M for in vivo HSC gene editing, while Ossium Health secured $126M using donor-derived bone marrow. HexemBio differentiates by rejuvenating a patient's own HSCs without genetic modification.
Aging Blood Drives Disease Burden
Declining HSC function contributes to blood cancers, immune dysfunction, and broader age-related diseases like neurodegeneration. Hematopoietic stem cell transplantation (HSCT) addresses some cases but faces limitations from aged cells. The HSCT market stands at $5.64B in 2026, projected to reach $8.57B by 2032 at 10.6% CAGR, driven by rising blood disorder incidence.
Yolk Sac Mimics Restore Youthful HSCs
HexemBio's platform recreates the embryonic yolk sac niche to treat patient HSCs ex vivo before IV reinfusion, avoiding gene editing or surgery. This approach, validated in a Nature publication, restores regenerative capacity naturally. Unlike Ensoma's genetic edits or Ossium's allogeneic cells, it uses autologous therapy for better compatibility.
As Tim Draper of Draper Associates shared:
"People don’t die of old age, they die of aging blood. As blood stem cells decline, immunity weakens, inflammation spreads, and disease follows. Fix the blood, and you change the trajectory."
Draper Backs Non-Editing Rejuvenation
Draper Associates led the round with participation from SOSV and Seraphim Space, signaling conviction in HexemBio's niche restoration over reprogramming. The funding follows FDA Orphan Drug Designation in July 2025 and a completed Pre-IND meeting in January 2026. Investors gain strategic validation from the star-studded advisory board.
HSCT Market Eyes Rejuvenation Shift
The space sees activity from ExCellThera, which reported positive Phase III results for HSC expansion in March 2026. Retro Biosciences advanced a Phase 1 autophagy trial amid plans for a $1B raise. HexemBio positions its method as a scalable alternative, targeting over 100 hematological diseases.
Elite Advisors Bolster Credibility
The advisory board features Robert Langer (MIT/Moderna), George Church (Harvard), and Joanne Kurtzberg (Duke BMT pioneer), alongside regulatory experts like Peter Barton Hutt (ex-FDA). Founders hail from MIT and UC Berkeley with DARPA awards and 90+ years of combined experience. This team supports progression toward human trials.
IND Filing Targets 2027 Trials
HexemBio plans IND submission in 2026, with first-in-patient dosing slated for Q1 2027, focusing initially on bone marrow transplant patients.